Ionis Pharmaceuticals price target raised to $65 from $62 at Piper Sandler

Piper Sandler raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $65 from $62 and keeps an Overweight rating on the shares following the on-time FDA approval for Dawnzera in hereditary angioedema in adult and pediatric patients 12 and over. The label is largely in-line with expectations, and Piper is encouraged by the company’s commentary around the experienced sales team in allergy and immunology and other commercial preparations, the analyst tells investors in a research note.